In addition, based on the promising preclinical data combining anti-OX40 treatment with surgery [36], a phase Ib trial of OX40 agonistic mAb MEDI6469 prior to definitive surgical resection is currently recruiting patients with locoregionally advanced HNSCC (NCT02274155). The gene discussed is TNFRSF4; the disease is head and neck squamous cell carcinoma.